よむ、つかう、まなぶ。
【参考資料6】抗微生物薬適正使用の手引き 第三版 補遺 (33 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
29. Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors
associated with early failure in hospitalized patients with community-acquired pneumonia.
Arch Intern Med. 2004 Mar;164(5):502-508.
30. Ioanas M, Ferrer M, Cavalcanti M. et al. Causes and predictors of nonresponse to treatment
of intensive care unit-acquired pneumonia. Crit Care Med. 2004 Apr;32(4):938-945.
31. Jang YR, Eom JS, Chung W, Cho YK. Prolonged fever is not a reason to change antibiotics
among patients with uncomplicated community-acquired acute pyelonephritis. Medicine
(Baltimore). 2019 Oct;98(43):e17720.
32. Hebeisen UP, Atkinson A, Marschall J, Buetti N. Catheter-related bloodstream infections with
coagulase-negative staphylococci: are antibiotics necessary if the catheter is removed?
Antimicrob Resist Infect Control. 2019 Jan;8:21.
33. Baddour LM, Wilson WR, Bayer AS. et al. Infective Endocarditis in Adults: Diagnosis,
Antimicrobial Therapy, and Management of Complications: A Scientific Statement for
Healthcare Professionals From the American Heart Association. Circulation. 2015
Oct;132(15):1435-1486.
34. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000
Oct;13(4):686-707.
35. 抗菌薬生涯教育テキスト. 第 3 版 環状リポペプチド系抗菌薬 2020.
36. Yim J, Smith JR, Rybak MJ. Role of Combination Antimicrobial Therapy for VancomycinResistant Enterococcus faecium Infections: Review of the Current Evidence.
Pharmacotherapy. 2017 May;37(5):579-592.
37. Shukla BS, Shelburne S, Reyes K. et al. Influence of Minimum Inhibitory Concentration in
Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time
to Change the Breakpoint? Clin Infect Dis. 2016 Jun;62(12):1514-1520.
38. LPSN-List of Prokaryotic names with Standing Nomenclature. at https://lpsn.dsmz.de/.)
39. Harris PNA, Tambyah PA, Lye DC. et al. Effect of Piperacillin-Tazobactam vs Meropenem on
30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and
Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA. 2018 Sep;320(10):984-994.
40. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases
Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant GramNegative Infections. Clin Infect Dis. 2023 Jul:ciad428.
41. Matsumura Y, Yamamoto M, Nagao M. et al. Emergence and spread of B2-ST131-O25b, B2ST131-O16 and D-ST405 clonal groups among extended-spectrum-beta-lactamaseproducing Escherichia coli in Japan. J Antimicrob Chemother. 2012 Nov;67(11):2612-2620.
42. Henderson A, Paterson DL, Chatfield MD. et al. Association Between Minimum Inhibitory
Concentration, Beta-lactamase Genes and Mortality for Patients Treated With
Piperacillin/Tazobactam or Meropenem From the MERINO Study. Clin Infect Dis. 2021
Dec;73(11):e3842-e3850.
43. Matsumura Y, Yamamoto M, Nagao M. et al. Multicenter retrospective study of cefmetazole
and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli
bacteremia. Antimicrob Agents Chemother. 2015 Sep;59(9):5107-5113.
33
associated with early failure in hospitalized patients with community-acquired pneumonia.
Arch Intern Med. 2004 Mar;164(5):502-508.
30. Ioanas M, Ferrer M, Cavalcanti M. et al. Causes and predictors of nonresponse to treatment
of intensive care unit-acquired pneumonia. Crit Care Med. 2004 Apr;32(4):938-945.
31. Jang YR, Eom JS, Chung W, Cho YK. Prolonged fever is not a reason to change antibiotics
among patients with uncomplicated community-acquired acute pyelonephritis. Medicine
(Baltimore). 2019 Oct;98(43):e17720.
32. Hebeisen UP, Atkinson A, Marschall J, Buetti N. Catheter-related bloodstream infections with
coagulase-negative staphylococci: are antibiotics necessary if the catheter is removed?
Antimicrob Resist Infect Control. 2019 Jan;8:21.
33. Baddour LM, Wilson WR, Bayer AS. et al. Infective Endocarditis in Adults: Diagnosis,
Antimicrobial Therapy, and Management of Complications: A Scientific Statement for
Healthcare Professionals From the American Heart Association. Circulation. 2015
Oct;132(15):1435-1486.
34. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000
Oct;13(4):686-707.
35. 抗菌薬生涯教育テキスト. 第 3 版 環状リポペプチド系抗菌薬 2020.
36. Yim J, Smith JR, Rybak MJ. Role of Combination Antimicrobial Therapy for VancomycinResistant Enterococcus faecium Infections: Review of the Current Evidence.
Pharmacotherapy. 2017 May;37(5):579-592.
37. Shukla BS, Shelburne S, Reyes K. et al. Influence of Minimum Inhibitory Concentration in
Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time
to Change the Breakpoint? Clin Infect Dis. 2016 Jun;62(12):1514-1520.
38. LPSN-List of Prokaryotic names with Standing Nomenclature. at https://lpsn.dsmz.de/.)
39. Harris PNA, Tambyah PA, Lye DC. et al. Effect of Piperacillin-Tazobactam vs Meropenem on
30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and
Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA. 2018 Sep;320(10):984-994.
40. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases
Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant GramNegative Infections. Clin Infect Dis. 2023 Jul:ciad428.
41. Matsumura Y, Yamamoto M, Nagao M. et al. Emergence and spread of B2-ST131-O25b, B2ST131-O16 and D-ST405 clonal groups among extended-spectrum-beta-lactamaseproducing Escherichia coli in Japan. J Antimicrob Chemother. 2012 Nov;67(11):2612-2620.
42. Henderson A, Paterson DL, Chatfield MD. et al. Association Between Minimum Inhibitory
Concentration, Beta-lactamase Genes and Mortality for Patients Treated With
Piperacillin/Tazobactam or Meropenem From the MERINO Study. Clin Infect Dis. 2021
Dec;73(11):e3842-e3850.
43. Matsumura Y, Yamamoto M, Nagao M. et al. Multicenter retrospective study of cefmetazole
and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli
bacteremia. Antimicrob Agents Chemother. 2015 Sep;59(9):5107-5113.
33